H. TANAKA

Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative

Masanori Baba, H. TANAKA, Erik De Clercq et al. · Biochemical and Biophysical Research Communications · 1989 · 287 citations

Medicinal Chemistry, Medicine, Immunology +7

Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.

Masanori Baba, Erik De Clercq, H. TANAKA et al. · Proceedings of the National Academy of Sciences · 1991 · 175 citations · Full text

Antiviral Drug, 5-Ethyl-6-phenylthiouracil Derivatives, Uracil Analogues +18

Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro

Masanori Baba, Shirô Shigeta, Satoshi Yuasa et al. · Antimicrobial Agents and Chemotherapy · 1994 · 117 citations · Full text

Specific Inhibitor, Immunology, Mt-4 Cells +16

Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)

H. TANAKA, Masanori Baba, Masaru Ubasawa et al. · Journal of Medicinal Chemistry · 1991 · 77 citations

Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives.

Masanori Baba, Erik De Clercq, H. TANAKA et al. · Molecular Pharmacology · 1991 · 75 citations